DXS International plc : AGM Statement Thomson Reuters



At today's AGM, David Immelman, CEO of DXS, the developer and supplier of clinical decision support systems to Clinical Commissioning Groups and healthcare professionals, will be making the following statement:

"We stated at the time of the final results that our turnover in the first quarter had increased by 10% and I am pleased to report that this trend is continuing.  The growth in revenues by the end of September 2014 rose by a further 12% and we have grown our client base by 8 CCG's since the year end bringing the total to 28 (approx. 1300 GP Practices).

During the course of last year, we recruited additional staff to ensure that DXS provides the level of service expected by our clients and GPSoC together with new systems to manage clinical safety.  As part of this process, we have made hires in Sales and Marketing, Technology, Content Management and Support.  We believe that we now have sufficient staff to take the business onto the next level. These resources are supported by new improved systems for support and content management solutions.

We are continuing to develop new products which we are planning to launch during 2015 and which we believe will enhance our current offering and I look forward to announcing those in due course."

Mr Immelman also informed shareholders that a video interview with Managing Director, Steven Bauer, was available at www.proactiveinvestors.co.uk or www.isdx.com.

We are confident for the future of DXS and look forward to reporting the results for the half year to 31 October 2014 in mid-December.


David Immelman, CE0

DXS International plc


01252 719800
City & Merchant Ltd (Corporate Adviser)  
David Papworth 0207 101 7676
MB Communications (Financial PR)  
Maxine Barnes 07860489571

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

The Directors of DXS International plc accept responsibility for this announcement.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DXS International plc via Globenewswire